Adasuve (loxapine) medical prior authorization
Customize your policy alerts
Sign up for AvMed Policy Pub. 100-2 alerts
Get alerted when Policy Pub. 100-2 changes without checking for updates manually.
Monitor payer policy activity
This form governs prior authorization and step-edit requests for Adasuve (loxapine aerosol) administered as an outpatient/medical benefit and applies to AvMed members and their prescribing providers.
No material clinical or coverage changes in this revision.
Coverage Criteria
inv-01: Initial Authorization — Covered when ALL of the following are met
Covered when ALL of the following are met:
chunk 4
chunk 5
chunk 5
chunk 5
chunks 3 and 5
chunk 3
inv-02: Reauthorization / Continuation — Reauthorization covered when ALL of the following are met
Reauthorization covered when ALL of the following are met:
chunk 4
chunk 4
Use of samples to initiate therapy does not meet preauthorization or step-edit criteria and will not be accepted. Previous therapies will be verified through pharmacy paid claims or submitted chart notes; providers should ensure documented evidence of prior treatment is included with the request.
Requests where the administration is not performed in a REMS-enrolled healthcare facility or that lack documentation confirming the member's diagnosis, documented agitation, and required supporting records (labs, diagnostics, chart notes) may be denied as not medically necessary. Providers must attest that Adasuve will be administered only in an enrolled facility to mitigate the risk of bronchospasm.
Coding & Quantity Limits
| J2062 | Injection, loxapine (Adasuve) aerosol powder breath activated (Medical) |
Provider Actions & Submission Requirements
Prior Authorization Required
Adasuve (loxapine aerosol powder, J2062) requires prior authorization when billed as a medical benefit. Requests must include a signed prescribing physician signature (preprinted stamps not valid). Incomplete, incorrect, or illegible submissions may delay or result in denial of authorization. For urgent reviews, contact AvMed Pre-Authorization if a standard review could seriously jeopardize the member's life, health, or function.
- Prior authorization required for Adasuve billed as J2062 (Medical).
- Fax completed request and supporting documentation to 1-877-535-1391.
- Prescriber signature required; preprinted stamps are not valid.
- Urgent review: contact AvMed Pre-Authorization per plan definition.
Samples and Prior Therapy Verification
Use of product samples to initiate therapy does not satisfy step-edit or preauthorization requirements. The provider must document prior therapies — previous treatments will be verified via pharmacy paid claims or submitted chart notes.
- Samples do NOT meet step-edit/preauthorization criteria.
- Prior therapy will be verified through pharmacy claims or chart documentation.
Required Submission Contents
All authorization requests must include the following: provider’s printed name and original signature, member and prescriber information, diagnosis, and supporting clinical documentation (e.g., chart notes, lab results, diagnostics) to justify the use of Adasuve for psychomotor agitation or approved diagnoses.
- Provider signature and printed name (signature must be original).
- Member name, ID, and prescriber contact information (phone/fax).
- Diagnosis (schizophrenia or bipolar I disorder) and documentation of psychomotor agitation where applicable.
- Supporting documentation: chart notes, labs, diagnostics as relevant.
Incomplete or Illegible Submission
If the request form or supporting documentation is incomplete, illegible, or missing required elements, the authorization may be delayed or denied. Ensure all phone and fax numbers on the form are correct to avoid unnecessary delays.
- Incomplete, incorrect, or illegible submissions may delay or result in denial of authorization.
- Ensure phone and fax numbers are accurate on the submission form.
Missing Clinical Documentation or REMS Compliance
Because loxapine (Adasuve) is subject to a REMS program for bronchospasm risk, requests missing documentation of REMS-compliant administration at an enrolled healthcare facility or lacking confirmation that the administering facility is REMS-certified may be denied.
- Requests lacking REMS facility confirmation or required REMS documentation may be denied.
- Adasuve must be administered only in an enrolled healthcare facility per REMS requirements.
Definitions
Initial Therapy Criteria
inv-14: Initial Therapy Criteria — initial authorization logic
Initial Authorization
chunks 4 and 5
chunk 5
chunk 5
chunk 3
Continuation / Reauthorization Criteria
inv-15: Continuation Therapy — reauthorization criteria logic
Reauthorization
chunk 4
chunk 4
Step Therapy Requirements
| Step | Requirement |
|---|---|
| 1 | Previous therapies must be verified through pharmacy paid claims or submitted chart notes; use of samples to initiate therapy does not satisfy the step-edit/preauthorization requirement. |
Site of Care / REMS Requirements
Administration only in REMS-enrolled facility (office, infusion center, hospital outpatient)
Adasuve must be administered only in a REMS-enrolled healthcare facility (office, infusion center, or hospital outpatient) to mitigate the risk of bronchospasm; the provider must attest to facility enrollment on the request.
- Permitted administration settings: physician office, infusion center, or hospital outpatient
- Provider attestation that administration will occur in a REMS-enrolled facility is required
Background
Adasuve (loxapine inhalation powder) is a rapidly absorbed antipsychotic indicated for acute agitation associated with schizophrenia or bipolar I disorder. Because inhaled loxapine can cause bronchospasm, its use is restricted to administration in REMS-enrolled healthcare facilities and providers must attest to facility enrollment when requesting coverage.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.